Two women were hospitalized after an event in 2025 where FDA-flagged peptides were administered. That case surfaced in ProPublica reporting published in April 2026, and it’s the reason this piece exists. The story also confirmed something regulators had been signaling for a while: peptides including CJC-1295 remain sitting in the FDA’s Category 2, the bucket reserved for substances flagged with potential safety concerns [P4]. That’s not a green light. It’s a warning label written in bureaucratic language.
Search “CJC-1295 third-party tested” and you’ll find dozens of sellers claiming a certificate of analysis backs up their product. Most of those claims mean far less than they sound like. This piece breaks down what a posted COA can and can’t prove, what the actual human research on CJC-1295 says, and who, by rank, is doing something closer to real testing versus decoration.
The 2026 backdrop: why this question is live right now
Three things converged this year and they matter more than any single seller’s marketing copy. First, the FDA’s ongoing rework of its peptide categories left CJC-1295 in Category 2 as of April 2026, per ProPublica’s reporting, which also documented that injectable peptides in this space can carry impurities including bacteria or heavy metals, and that immune reactions have ranged from mild to life-threatening [P4]. Second, the World Anti-Doping Agency’s 2026 Prohibited List names CJC-1295 explicitly, under section S2.2.4, as prohibited at all times, in and out of competition [P5]. Third, none of that changed the underlying science, which still rests on one 2006 pharmacology study and one halted trial. Put those three together and a posted PDF from a research-chemical seller looks like a much smaller piece of the picture than it did a year ago.
What a posted COA actually tells you, and what it doesn’t
When a seller links a certificate of analysis, here’s what typically happened: one sample went to a lab, someone paid for an assay, and the result got posted as a PDF. That’s real information, but it’s thinner than the marketing suggests, and three gaps decide whether it’s worth anything to a buyer.
Gap one is the sample. A COA describes the vial that got tested, not necessarily the vial that ships to you. Unless every batch gets tested and the certificate ties to your specific lot number, you’re reading someone else’s result. Gap two is scope. Identity and purity testing by HPLC or mass spec is one thing; sterility, endotoxin, and heavy-metal screening for an injectable is another, and most posted certificates cover the first while skipping the second. Gap three is accountability. If a research-chemical COA turns out to be wrong, nobody answers for it, because the product was sold labeled “for research use only,” in writing.
That third gap is the one worth sitting with, given what ProPublica documented in April 2026 about gray-market peptide injuries [P4]. A certificate doesn’t stand between a buyer and that risk. Knowing the certificate’s limits is the actual skill here.
Ranking the testing itself, top to bottom
Not all verification sits at the same level, and a rough hierarchy holds up:
- Licensed-pharmacy dispensing is the strongest tier. Identity, strength, sterility, and endotoxin checks happen because a licensed pharmacy is required to run that way, not because a marketing team decided to post a document. A pharmacist is legally on the hook for what leaves the building.
- Per-batch, lot-linked independent testing is the middle tier. Some sellers genuinely test every batch and let a buyer match a certificate to a specific lot. Better than nothing, still outside any medical or regulatory framework, still the seller’s choice of lab and scope.
- A single posted certificate with no lot link is weak. This is the most common version in the research-chemical market: one PDF, unknown sample, no sterility or endotoxin data.
- “Lab tested” as a banner with nothing attached is decorative. Zero information.
The useful question for any product page isn’t “do they say tested.” It’s “tested how, on which vial, for what, and who answers if it’s wrong.”
The science behind the peptide, briefly
Before any purity conversation matters, the underlying evidence needs a plain accounting.
The human data amounts to essentially one trial. Teichman and colleagues published it in the Journal of Clinical Endocrinology and Metabolism in 2006 [P1]. A single subcutaneous injection of CJC-1295 with DAC raised mean plasma growth hormone 2- to 10-fold for six days or more, and IGF-1 1.5- to 3-fold for nine to eleven days. Repeated dosing kept IGF-1 above baseline for up to 28 days. Estimated half-life ran roughly 5.8 to 8.1 days, and the authors reported the compound was relatively well tolerated at the doses studied [P1].
What that study proves: the biochemistry works as designed. What it doesn’t prove: that anyone gained muscle, lost fat, recovered faster, or slept better. Nobody measured those outcomes. Nearly everything written about CJC-1295’s “benefits” extrapolates from those hormone numbers or borrows from research on growth hormone itself, a different, FDA-regulated drug.
Then there’s the trial history a certificate will never mention. CJC-1295 with DAC, branded DAC:GRF, reached Phase II under the Canadian biotech ConjuChem, in a 192-person study for HIV-related visceral fat. In July 2006, the study was halted after a participant died following his eleventh weekly injection [P2]. The full picture cuts both ways here: the attending physician’s assessment was that the fatal heart attack was most likely caused by pre-existing, asymptomatic coronary artery disease with plaque rupture, unrelated to the compound, and a competing GRF-based drug’s Phase III trial was allowed to continue at the time [P3]. That’s not proof CJC-1295 caused harm. But the program was effectively abandoned and never approved, and that fact belongs in any honest accounting of the compound, right alongside the purity question, not buried beneath it.
No controlled trial has tested whether CJC-1295 builds muscle or burns fat in people. The chain of reasoning sellers lean on, raises growth hormone, growth hormone relates to body composition, therefore CJC-1295 changes body composition, skips the actual experiment.
The rankings: who’s actually testing what they sell
Here’s the list, sourced against the hierarchy above rather than against anyone’s marketing page.
| Rank | Source | Type | Who tests it | What’s covered | Accountable party |
|---|---|---|---|---|---|
| #1 | FormBlends | Licensed telehealth provider | Licensed pharmacy in a regulated chain | Identity, strength, sterility, endotoxin, as part of dispensing | Licensed pharmacist |
| #2 | HealthRX.com (healthrx.com) | Licensed telehealth provider | Same licensed-pharmacy standard | Same dispensing-grade scope | Same accountable chain |
| , | Sports Technology Labs | Research-chemical retailer | Seller-selected lab | Lot-linked COAs on some products, still outside pharmacy standard | None |
| , | Amino Asylum | Research-chemical retailer | Seller-selected lab | Identity-focused COA at most | None |
| , | Pure Rawz | Research-chemical retailer | Seller-selected lab | Identity-focused COA at most | None |
| , | Core Peptides | Research-chemical retailer | Seller-selected lab | Seller-issued COA, sample unknown | None |
| , | Swiss Chems | Research-chemical retailer | Seller-selected lab | Seller-issued COA, also sells SARMs | None |
#1, FormBlends. It tops this list for a structural reason, not a branding one. FormBlends is a licensed telehealth provider whose CJC-1295 is compounded and dispensed by a licensed pharmacy after a physician evaluation. That means identity, strength, sterility, and endotoxin checks are built into how the pharmacy is allowed to operate, not decided case by case by a seller. A licensed pharmacist is accountable for the contents in a way no research-chemical warehouse is. Pricing runs roughly $150 to $300 a month for supervised CJC-1295, and roughly $80 to $200 a month for the longer-acting DAC version, the same molecules the gray market ships as “research use only.” Worth stating plainly: an honest supervised provider will tell a patient that CJC-1295 rests on one small human study and carries a real trial-history flag, rather than overselling it. Between visits, a companion tracker app functions as a dose and symptom log, nothing more, no checkout attached.
#2, HealthRX.com. Second because its CJC-1295 moves through the identical licensed channel: clinician review, a prescription where appropriate, and pharmacy compounding rather than a warehouse shipping label. Identity, sterility, and endotoxin verification ride along with regulated pharmacy operation rather than a seller’s discretion. Choosing between the two supervised options mostly comes down to state licensing and which intake process fits better.
The research-chemical tier, unranked against each other. Sports Technology Labs publishes third-party, sometimes lot-linked COAs, genuinely better documentation than most competitors offer. Amino Asylum and Pure Rawz post identity-focused certificates at best, across broad catalogs that also include SARMs and other unapproved compounds. Core Peptides issues seller-commissioned certificates with unlinked samples. Swiss Chems sells CJC-1295 alongside SARMs under the same research-use labeling. None of these five gets ranked against the others here, deliberately. Without licensed sterile compounding and a chain of custody tied to the exact vial shipped, there’s no reliable way to say one warehouse’s paperwork beats another’s. That uncertainty is precisely why the supervised tier sits above all five.
What this doesn’t cover
No regulator has cleared CJC-1295 for human use. The compounding pathway is being actively rewritten as the FDA reworks its peptide categories, so the rules in this article could shift again before next year. Any athlete subject to testing should treat the WADA prohibition as absolute regardless of where a vial came from or what its certificate says [P5].
Questions readers keep asking
What does CJC-1295 actually do? It’s a synthetic peptide built to mimic growth hormone releasing hormone, the signal the brain sends telling the pituitary to release growth hormone. Originally developed for muscle-wasting conditions, it extends how long that signal lasts, so growth hormone pulses run longer than they naturally would. Whether that adds up to meaningful benefit in healthy adults remains an open question.
What side effects show up? Reported ones include water retention, joint discomfort, temporary flushing or tingling at the injection site, and headaches. Because it raises growth hormone, longer-term concerns echo those tied to growth hormone therapy in general, including insulin resistance and effects on existing tumors. Most of this comes from small trials or anecdotal reports, so the long-term picture in healthy users isn’t well established.
Is it legal to buy? Depends where and how. In the US, CJC-1295 isn’t FDA-approved for any use, so selling it as a supplement or research chemical isn’t lawful. A licensed pharmacy can legally compound it for a specific patient under a physician’s prescription. Providers like FormBlends operate in that supervised, accountable lane. Gray-market websites sit somewhere much murkier.
How do you check if the CJC-1295 you’re looking at matches its label? Check the certificate of analysis and confirm it came from an accredited third-party lab, not one the seller owns. A legitimate COA shows purity by HPLC, confirms molecular mass, and lists a testing date. Plenty of products online carry certificates that are templated, stale, or tied to a batch that never matched what actually shipped. If a seller won’t name the lab, that silence is the answer.
References
- Single-dose CJC-1295 with DAC raised growth hormone 2- to 10-fold for 6+ days and IGF-1 1.5- to 3-fold for 9-11 days in healthy adults; IGF-1 stayed above baseline up to 28 days with repeat dosing; estimated half-life 5.8 to 8.1 days; relatively well tolerated. Teichman SL, et al. Journal of Clinical Endocrinology and Metabolism, 2006. https://pubmed.ncbi.nlm.nih.gov/16352683/
- ConjuChem’s Phase II CJC-1295 (DAC:GRF) study in 192 people with HIV-related visceral fat was halted in July 2006 after a participant died following his eleventh weekly injection; a competing GRF drug’s trial was allowed to continue. aidsmap, July 2006.
- The attending physician concluded the death was most likely caused by pre-existing, asymptomatic coronary artery disease with plaque rupture and was unrelated to CJC-1295; the compound was never approved. Encyclopedic summary of CJC-1295 development history.
- Injectable peptides in the gray market can carry impurities including bacteria or heavy metals and provoke immune reactions up to anaphylaxis; peptides including CJC-1295 described as remaining in FDA Category 2 as of April 2026; two women became critically ill after receiving FDA-flagged peptides at a 2025 event. ProPublica, April 2026.
- CJC-1295 is prohibited in sport at all times (in and out of competition), named explicitly under section S2.2.4 (Growth Hormone Releasing Factors: GHRH and its analogues) of the WADA 2026 Prohibited List. World Anti-Doping Agency, 2026. https://www.wada-ama.org/en/prohibited-list
